Anika Therapeutics, Inc. 10-K filing
Filed 2026-03-03 · Report date 2025-12-31 · 2025 FY
Filing metadata
- Accession number
- 0001171843-26-001275
- Form type
- 10-K
- CIK
- 0000898437
- Primary document
- https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Anika Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $112.8M | - | - |
| Cost Of Revenue | $49.0M | - | - |
| Gross Profit | $63.8M | - | - |
| Operating Income | $-11.1M | - | - |
| Net Income | $-10.9M | - | - |
| Eps Basic | -0.76 | - | - |
| Eps Diluted | -0.76 | - | - |
| Cash And Equivalents | $57.5M | - | - |
| Total Assets | $190.3M | - | - |
| Shareholders Equity | $143.5M | - | - |
| Operating Cash Flow | $11.2M | - | - |
| Capital Expenditures | $6.8M | - | - |